

Alberto Morales

EDUCATION

Texas A&M University Bachelors of Science in Biomedical Engineering	College Station, TX 2017 - 2021
Texas A&M University - Corpus Christi Masters of Science in Chemistry	Corpus Christi, TX 2024 - <i>est.</i> 2026

EXPERIENCE

Harte Research Institute Graduate Research Assistant	Corpus Christi, TX January 2024 - Present
Kumon Reading and Math Tutor	Irving, TX August 2023 - December 2023
Abbott, Abbott Molecular Field Service Engineer	Dallas, TX August 2022 - August 2023
Rio Grande Valley Clinical Research Institute Clinical Research Coordinator	Pharr, TX December 2021 - July 2022
Family Medical Day & Night Clinic Medical Scribe / Assistant	Pharr, TX October 2021 - February 2022
Dr. Mary McDougall NMR RF Lab Undergraduate Research Assistant	College Station, TX May 2019 - May 2021
Texas A&M University Physics Department Peer Teacher (Experimental Physics and Engineering III)	College Station, TX August 2019 - December 2020
American Biochemicals Inc. Lab Technician	College Station, TX March 2019 - July 2019
Texas Diabetes Institute Lab Technician (Internship)	San Antonio, TX December 2018/2019 – January 2019/2020

CERTIFICATIONS & LICENSURE

Abbott Laboratories, Certificate of Proficiency, VIP	May 2022
Abbott Laboratories, Certificate of Proficiency, Alinity M	September 2022
Collaborative Institutional Training Initiative (CITI) Good Clinical Practice	December 2021 - December 2023
Mayo Medical Laboratories IATA Certification	December 2021 - December 2023

RESEARCH EXPERIENCE

1. A Phase III Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 week Variable Length study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® Pressurized MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS)
2. A Phase III randomized, multi-center, open label study to assess the efficacy, safety, and tolerability of monoclonal antibody VIR-7831 (sotrovimab) given intramuscularly versus intravenously for the treatment of mild/moderate coronavirus disease 2019 (COVID-19) in high risk non-hospitalized patients.
3. A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 compared with mepolizumab or benralizumab.
4. A 52-week, randomised, double-blind, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic phenotype
5. A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir (JNJ-53718678) in Adult Outpatients with Respiratory Syncytial Virus (RSV) Infection who are at High Risk for RSV-related Disease Progression
6. A 52-week, randomized, double-blind, double-dummy, placebo- and active- controlled (Roflumilast, Daliresp® 500µg), parallel group, study to evaluate the efficacy and safety of two doses of CHF6001 DPI add-on to maintenance triple therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis
7. A phase 3, randomized, double-blind, 23 month long study that is designed to evaluate the safety profile of the 20-valent pneumococcal conjugate vaccine (20vPnC) in healthy infants. B7471013 contains 4 doses of the 20-valent pneumococcal conjugate vaccine (20vPnC) which are based on the 13-valent pneumococcal conjugate vaccine (13vPnC) vaccine
8. Developed software and Graphic User Interface (GUI) for a repurposed 3D printer design to take precise measurements of the inside of RF coils.
9. Designed and prototyped a power system for a three-element coil for spectroscopy and imaging.